UiPath, Inc. (PATH) Stock Analysis

Q: What is the PATH stock price target?

Take-profit $12.42 (+22.1% upside). Prior stop was $9.46.

Q: What are the risks of investing in PATH?

Concentration risk — Product: UiPath Platform; Leverage penalty (D/E 3.9): -1.5; Elevated risk factors; Momentum score 4.3/10 — below 4.5 minimum; Death cross — 50-day MA below 200-day MA.

Q: Is PATH overvalued or undervalued?

UiPath, Inc. trades at a P/E of 20.0 (forward 11.6). TrendMatrix value score: 8.2/10. Overall verdict: Sell.

Q: What do analysts say about PATH?

28 analysts cover PATH with a consensus score of 3.4/5. Average price target: $14.

Recovery setup · Catalyst-Driven edge

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-05-01

Technology · Software - Infrastructure

Sell if holding. Momentum 4.3/10 is below the 5.0 floor at $10.16 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 3.9): -1.5; Concentration risk — Product: UiPath Platform.

UiPath provides an enterprise agentic automation platform (UiPath Platform™) combining RPA, AI agents, process orchestration, and governance capabilities, primarily selling to large enterprises globally via direct and channel sales. Revenue is subscription-based; a limited... Read more

$10.16+22.1% A.UpsideScore 6.3/10#8 of 80 Software - Infrastructure

Stop $9.46Target $12.42(analyst − 10%)A.R:R 2.0:1

Analyst target$13.80+35.9%16 analysts

$12.42our TP

$10.16price

$13.80mean

$17

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 28d clear, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.

Thesis

Rewards

Strong earnings beat streak (3/4)

High-quality business

Attractive valuation

Risks

Concentration risk — Product: UiPath Platform

Leverage penalty (D/E 3.9): -1.5

Elevated risk factors

Key Metrics

P/E (TTM)20.0

P/E (Fwd)11.6

Mkt Cap$5.4B

EV/EBITDA53.6

Profit Mgn17.5%

ROE14.4%

Rev Growth13.6%

Beta1.02

DividendNone

Rating analysts28

Quality Signals

Piotroski F8/9

Options Flow

P/C0.79neutral

IV88%elevated

Max Pain$5-50.8% vs spot

Concentration Risks(10-K Item 1A)

HIGHProductUiPath Platform
10-K Item 1A: 'Because we derive substantially all of our revenue from our UiPath Platform™, failure of this platform to satisfy customer demands could adversely affect our business'

Material Events(8-K, last 90d)

2026-03-25Item 5.02LOW
UiPath appointed Raghavendra Malpani as Chief Product and Technology Officer effective March 25, 2026, promoted from his role as CTO. No change in reporting structure noted.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

10 dimensions · all in-band

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value8.215%1.23

Quality7.115%1.06

Growth8.015%1.20

Momentum4.310%0.43

Sentiment6.410%0.64

Insider Activity5.010%0.50

Peer Rank5.310%0.53

Technical Setup4.25%0.21

Risk Profile3.15%0.16

Catalyst7.55%0.38

Overall (Σ contributions)6.34

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

GatesMomentum 4.3<4.5Death cross (50MA < 200MA)A.R:R 2.0 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 28d clearSEMI CYCLE PEAK CLEARRecoverySuitability: Moderate

RSI

61 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $9.28Resistance $11.42

Price Targets

$12

A.Upside+22.2%

A.R:R2.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeCautious

Risk Alerts

! Momentum score 4.3/10 — below 4.5 minimum

! Death cross — 50-day MA below 200-day MA

Earnings

3/4 beats

Next Earnings2026-05-28 (28d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is PATH stock a buy right now?

Sell if holding. Momentum 4.3/10 is below the 5.0 floor at $10.16 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 3.9): -1.5; Concentration risk — Product: UiPath Platform. Chart setup: Death cross but MACD improving, RSI 61. Prior stop was $9.46. Score 6.3/10, moderate confidence.

What is the PATH stock price target?

Take-profit target: $12.42 (+22.1% upside). Prior stop was $9.46. Stop-loss: $9.46.

What are the risks of investing in PATH?

Concentration risk — Product: UiPath Platform; Leverage penalty (D/E 3.9): -1.5; Elevated risk factors.

Is PATH overvalued or undervalued?

UiPath, Inc. trades at a P/E of 20.0 (forward 11.6). TrendMatrix value score: 8.2/10. Verdict: Sell.

What do analysts say about PATH?

28 analysts cover PATH with a consensus score of 3.4/5. Average price target: $14.

What does UiPath, Inc. do?UiPath provides an enterprise agentic automation platform (UiPath Platform™) combining RPA, AI agents, process...